tiprankstipranks
Oruka Therapeutics, Inc. (ORKA)
NASDAQ:ORKA
US Market
ORKA
Oruka Therapeutics
RESEARCH TOOLSreports
Want to see ORKA full AI Analyst Report?

Oruka Therapeutics (ORKA) Stock Forecast & Price Target

815 Followers
See the Price Targets and Ratings of:

ORKA Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Oruka
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ORKA Stock 12 Month Forecast

Average Price Target

$137.25
▲(99.14% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Oruka Therapeutics in the last 3 months. The average price target is $137.25 with a high forecast of $200.00 and a low forecast of $45.00. The average price target represents a 99.14% change from the last price of $68.92.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","57":"$57","105":"$105","153":"$153","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":137.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$137.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,57,105,153,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.58,73.15076923076923,83.72153846153846,94.2923076923077,104.86307692307693,115.43384615384616,126.00461538461539,136.57538461538462,147.14615384615385,157.71692307692308,168.2876923076923,178.85846153846154,189.4292307692308,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.58,68.32384615384615,74.06769230769231,79.81153846153846,85.55538461538461,91.29923076923077,97.04307692307692,102.78692307692307,108.53076923076924,114.27461538461539,120.01846153846154,125.7623076923077,131.50615384615384,{"y":137.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.58,61.22769230769231,59.87538461538461,58.52307692307692,57.17076923076923,55.818461538461534,54.466153846153844,53.113846153846154,51.761538461538464,50.40923076923077,49.05692307692308,47.70461538461538,46.35230769230769,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.69,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.43,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$200.00Average Price Target$137.25Lowest Price Target$45.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on ORKA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$125
Buy
81.37%
Upside
Reiterated
05/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alcon (NYSE: ALC) and Oruka Therapeutics (NASDAQ: ORKA)
H.C. Wainwright Analyst forecast on ORKA
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$120
Buy
74.11%
Upside
Reiterated
05/18/26
Oruka: Strong ORKA-001 Clinical Profile and Pipeline Momentum Support Reiterated Buy Rating and Unchanged $120 Price Target
Piper Sandler Analyst forecast on ORKA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$75→$180
Buy
161.17%
Upside
Reiterated
05/14/26
Piper Sandler Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)
Wedbush Analyst forecast on ORKA
David Nierengarten
Wedbush
Wedbush
$165
Buy
139.41%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (NASDAQ: ASRT), Aytu BioScience (NASDAQ: AYTU) and Oruka Therapeutics (NASDAQ: ORKA)
BTIG Analyst forecast on ORKA
Julian Harrison
BTIG
BTIG
$151
Buy
119.09%
Upside
Reiterated
05/13/26
Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position
TD Cowen Analyst forecast on ORKA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/13/26
Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential
Barclays Analyst forecast on ORKA
Etzer Darout
Barclays
Barclays
$160
Buy
132.15%
Upside
Assigned
05/13/26
Barclays Remains a Buy on Oruka Therapeutics (ORKA)
Leerink Partners Analyst forecast on ORKA
David Risinger
Leerink Partners
Leerink Partners
$109→$120
Buy
74.11%
Upside
Reiterated
04/30/26
Oruka Therapeutics price target raised to $120 from $109 at LeerinkOruka Therapeutics price target raised to $120 from $109 at Leerink
Stifel Nicolaus Analyst forecast on ORKA
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$72→$150
Buy
117.64%
Upside
Reiterated
04/28/26
Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
UBS Analyst forecast on ORKA
Michael Yee
UBS
UBS
$75→$100
Buy
45.10%
Upside
Assigned
04/28/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS) and Oruka Therapeutics (NASDAQ: ORKA)
Guggenheim Analyst forecast on ORKA
Yatin Suneja
Guggenheim
Guggenheim
$125→$200
Buy
190.19%
Upside
Reiterated
04/27/26
Oruka Therapeutics price target raised to $200 from $125 at GuggenheimOruka Therapeutics price target raised to $200 from $125 at Guggenheim
Clear Street Analyst forecast on ORKA
Kaveri Pohlman
Clear Street
Clear Street
$71→$131
Buy
90.08%
Upside
Reiterated
04/27/26
Oruka Therapeutics price target raised to $131 from $71 at Clear StreetOruka Therapeutics price target raised to $131 from $71 at Clear Street
Jefferies Analyst forecast on ORKA
Roger Song
Jefferies
Jefferies
$45
Buy
-34.71%
Downside
Reiterated
03/11/26
Jefferies Remains a Buy on Oruka Therapeutics (ORKA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on ORKA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$125
Buy
81.37%
Upside
Reiterated
05/23/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alcon (NYSE: ALC) and Oruka Therapeutics (NASDAQ: ORKA)
H.C. Wainwright Analyst forecast on ORKA
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$120
Buy
74.11%
Upside
Reiterated
05/18/26
Oruka: Strong ORKA-001 Clinical Profile and Pipeline Momentum Support Reiterated Buy Rating and Unchanged $120 Price Target
Piper Sandler Analyst forecast on ORKA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$75→$180
Buy
161.17%
Upside
Reiterated
05/14/26
Piper Sandler Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)
Wedbush Analyst forecast on ORKA
David Nierengarten
Wedbush
Wedbush
$165
Buy
139.41%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (NASDAQ: ASRT), Aytu BioScience (NASDAQ: AYTU) and Oruka Therapeutics (NASDAQ: ORKA)
BTIG Analyst forecast on ORKA
Julian Harrison
BTIG
BTIG
$151
Buy
119.09%
Upside
Reiterated
05/13/26
Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position
TD Cowen Analyst forecast on ORKA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/13/26
Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential
Barclays Analyst forecast on ORKA
Etzer Darout
Barclays
Barclays
$160
Buy
132.15%
Upside
Assigned
05/13/26
Barclays Remains a Buy on Oruka Therapeutics (ORKA)
Leerink Partners Analyst forecast on ORKA
David Risinger
Leerink Partners
Leerink Partners
$109→$120
Buy
74.11%
Upside
Reiterated
04/30/26
Oruka Therapeutics price target raised to $120 from $109 at LeerinkOruka Therapeutics price target raised to $120 from $109 at Leerink
Stifel Nicolaus Analyst forecast on ORKA
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$72→$150
Buy
117.64%
Upside
Reiterated
04/28/26
Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
UBS Analyst forecast on ORKA
Michael Yee
UBS
UBS
$75→$100
Buy
45.10%
Upside
Assigned
04/28/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS) and Oruka Therapeutics (NASDAQ: ORKA)
Guggenheim Analyst forecast on ORKA
Yatin Suneja
Guggenheim
Guggenheim
$125→$200
Buy
190.19%
Upside
Reiterated
04/27/26
Oruka Therapeutics price target raised to $200 from $125 at GuggenheimOruka Therapeutics price target raised to $200 from $125 at Guggenheim
Clear Street Analyst forecast on ORKA
Kaveri Pohlman
Clear Street
Clear Street
$71→$131
Buy
90.08%
Upside
Reiterated
04/27/26
Oruka Therapeutics price target raised to $131 from $71 at Clear StreetOruka Therapeutics price target raised to $131 from $71 at Clear Street
Jefferies Analyst forecast on ORKA
Roger Song
Jefferies
Jefferies
$45
Buy
-34.71%
Downside
Reiterated
03/11/26
Jefferies Remains a Buy on Oruka Therapeutics (ORKA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oruka Therapeutics

3 Months
Julian HarrisonBTIG
Success Rate
7/9 ratings generated profit
78%
Average Return
+57.12%
Copying Julian Harrison's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +57.12% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
9/11 ratings generated profit
82%
Average Return
+191.34%
Copying David Risinger's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +191.34% per trade.
2 Years
David RisingerLeerink Partners
Success Rate
10/11 ratings generated profit
91%
Average Return
+261.84%
Copying David Risinger's trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +261.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ORKA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
13
9
14
23
28
Buy
4
3
5
9
10
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
12
19
32
38
In the current month, ORKA has received 38 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ORKA average Analyst price target in the past 3 months is 137.25.
Each month's total comprises the sum of three months' worth of ratings.

ORKA Financial Forecast

ORKA Earnings Forecast

Next quarter’s earnings estimate for ORKA is -$0.51 with a range of -$0.67 to -$0.41. The previous quarter’s EPS was -$0.48. ORKA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.
Next quarter’s earnings estimate for ORKA is -$0.51 with a range of -$0.67 to -$0.41. The previous quarter’s EPS was -$0.48. ORKA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.
No data currently available

ORKA Sales Forecast

Next quarter’s sales forecast for ORKA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ORKA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.
Next quarter’s sales forecast for ORKA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ORKA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ORKA has Performed in-line its overall industry.

ORKA Stock Forecast FAQ

What is ORKA’s average 12-month price target, according to analysts?
Based on analyst ratings, Oruka Therapeutics, Inc.’s 12-month average price target is 137.25.
    What is ORKA’s upside potential, based on the analysts’ average price target?
    Oruka Therapeutics, Inc. has 99.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ORKA a Buy, Sell or Hold?
          Oruka Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Oruka Therapeutics, Inc.’s price target?
            The average price target for Oruka Therapeutics, Inc. is 137.25. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $200.00 ,the lowest forecast is $45.00. The average price target represents 99.14% Increase from the current price of $68.92.
              What do analysts say about Oruka Therapeutics, Inc.?
              Oruka Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of ORKA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.